Showing results (1-10 of 406) with videos related to
Sort By:
Pageof 41
Diabetes Research and Clinical Practice|October 1, 2015
mTOR inhibitors and diabetesBruno Vergès, Bertrand CariouEuropean Journal of Endocrinology|October 25, 2013
Endocrine side effects of anti-cancer drugs: effects of anti-cancer targeted therapies on lipid and glucose metabolismBruno Vergès, Thomas Walter, Bertrand CariouAnnales D'Endocrinologie|August 22, 2018
Expert opinion on immunotherapy induced diabetesSarra Smati, Perrine Buffier, Benjamin Bouillet, et al.Annales D'Endocrinologie|August 27, 2018
Expert opinion on the metabolic complications of mTOR inhibitorsBenjamin Bouillet, Perrine Buffier, Sarra Smati, et al.Atherosclerosis|September 6, 2011
Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetesBruno Vergès, Laurence Duvillard, Marie Claude Brindisi, et al.Cardiovascular Diabetology|November 16, 2022
Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanismsBruno Vergès, Victor Aboyans, Denis Angoulvant, et al.Bulletin Du Cancer|February 22, 2014
[Management of metabolic disorders induced by everolimus in patients with differentiated neuroendocrine tumors: expert proposals]Catherine Lombard-Bohas, Bertrand Cariou, Bruno Vergès, et al.La Revue Du Praticien|January 12, 2016
[A YOUNG MAN WHOSE LDL-CHOLESTEROL IS GREATER THAN 1.9 G/L]Bertrand CariouDiabetes, Obesity & Metabolism|January 11, 2022
The metabolic triad of non-alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatmentBertrand CariouExpert Opinion on Pharmacotherapy|February 18, 2011
Combination lipid therapy in type 2 diabetes mellitusBruno VergèsPageof 41